ReviewBritish journal of pharmacology2013
The case for induced pluripotent stem cell-derived cardiomyocytes in pharmacological screening.
Review in British journal of pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Matured hiPSC-derived cardiomyocytes possess dematuration plasticity.Journal of molecular and cellular cardiology plus · 2025Article
- In heart failure reactivation of RNA-binding proteins is associated with the expression of 1,523 fetal-specific isoforms.PLoS computational biology · 2022Article
- Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection.Communications biology · 2021Article
- Comparison of the Simulated Response of ThreeFrontiers in pharmacology · 2021Article
- Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1PACS medicinal chemistry letters · 2020Article
- A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential.Toxicological sciences : an official journal of the Society of Toxicology · 2020Article
- Comparative effects of parent and heated cinnamaldehyde on the function of human iPSC-derived cardiac myocytes.Toxicology in vitro : an international journal published in association with BIBRA · 2019Article
- Optimizing Blended Collagen-Fibrin Hydrogels for Cardiac Tissue Engineering with Human iPSC-derived Cardiomyocytes.ACS biomaterials science & engineering · 2019Article
- High-content phenotypic assay for proliferation of human iPSC-derived cardiomyocytes identifies L-type calcium channels as targets.Journal of molecular and cellular cardiology · 2019Article
- Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip system.Biomaterials · 2018Article
- Article
- Article
- Engraftment and morphological development of vascularized human iPS cell-derived 3D-cardiomyocyte tissue after xenotransplantation.Scientific reports · 2017Article
- Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes.Cellular and molecular life sciences : CMLS · 2017Review
- Concise Review: Criteria for Chamber-Specific Categorization of Human Cardiac Myocytes Derived from Pluripotent Stem Cells.Stem cells (Dayton, Ohio) · 2017Review
- Steps toward Maturation of Embryonic Stem Cell-Derived Cardiomyocytes by Defined Physical Signals.Stem cell reports · 2017Article
- Period doubling cascades of limit cycles in cardiac action potential models as precursors to chaotic early Afterdepolarizations.BMC systems biology · 2017Article
- Identification of potent tricyclic prodrug S1PMedChemComm · 2017Article
- Back and forth in time: Directing age in iPSC-derived lineages.Brain research · 2017Review
- Stem Cells in Neurotoxicology/Developmental Neurotoxicology: Current Scenario and Future Prospects.Molecular neurobiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The current drug screening models are deficient, particularly in detecting cardiac side effects. Human stem cell-derived cardiomyocytes could aid both early cardiotoxicity detection and novel drug discovery. Work over the last decade has generated human embryonic stem cells as potentially accurate sources of human cardiomyocytes, but ethical constraints and poor efficacy in establishing cell lines limit their use. Induced pluripotent stem cells do not require the use of human embryos and have the added advantage of producing patient-specific cardiomyocytes, allowing both generic and disease- and patient-specific pharmacological screening, as well as drug development through disease modelling. A critical question is whether sufficient standards have been achieved in the reliable and reproducible generation of 'adult-like' cardiomyocytes from human fibroblast tissue to progress from validation to safe use in practice and drug discovery. This review will highlight the need for a new experimental system, assess the validity of human induced pluripotent stem cell-derived cardiomyocytes and explore what the future may hold for their use in pharmacology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.